TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29764464

Group type: EXPERIMENTAL
Intervention: DayTime (DT) casein supplementation
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: NightTime (NT) casein supplementation
Number of subjects: 13
Study: 28446141

Group type: EXPERIMENTAL
Intervention: Breast Cancer e‐Support program (mobile application) plus routine care
Number of subjects: 108

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 108
Study: 27268415

Group type: EXPERIMENTAL
Intervention: VIPP-Twins intervention (five biweekly sessions, home visits, videotaped interactions, positive feedback)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: VIPP-Twins intervention
Number of subjects: 225
Study: 23406256

Group type: EXPERIMENTAL
Intervention: Intensive anti-inflammatory agents (intravitreal and sub-Tenon's triamcinolone, oral flurbiprofen, and guttae prednisolone 1.0%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study: 21211651

Group type: EXPERIMENTAL
Intervention: Low-dose fluticasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Montelukast
Number of subjects: 0
Study: 19948624

Group type: EXPERIMENTAL
Intervention: Parent mentors (PMs) intervention
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Parent mentors (PMs) intervention (high participants)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Traditional asthma care (control group)
Number of subjects: 220
Study: 17845685

Group type: EXPERIMENTAL
Intervention: Furazolidone-based regimens (primary proton pump inhibitor-based)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Furazolidone-based regimens
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ranitidine bismuth citrate + furazolidone-based triple regimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: H(2) antagonist + furazolidone + one other antibiotic
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bismuth-based triple therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Primary quadruple regimens containing furazolidone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Second-line schedules containing furazolidone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Third-line 'rescue' therapies
Number of subjects: 0
Study: 15485440

Group type: EXPERIMENTAL
Intervention: NavX-guided ablation (group II, 20 patients)
Number of subjects: 40
Study: 11524192

Group type: EXPERIMENTAL
Intervention: Topical anesthesia plus intracameral lidocaine 1%
Number of subjects: 60

Group type: COMPARATOR
Intervention: Retrobulbar anesthesia
Number of subjects: 60
Study: 9773784

Group type: EXPERIMENTAL
Intervention: Uremic patients
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 29
Study: 8568016

Group type: EXPERIMENTAL
Intervention: Nicoderm (nicotine transdermal system), 21 mg/day applied for 24 hours
Number of subjects: 14

Group type: COMPARATOR
Intervention: Controlled smoking (30 cigarettes at half‐hourly intervals on days 1 and 5; ad libitum smoking on days 2‐4)
Number of subjects: 14
Study: 2754147

Group type: EXPERIMENTAL
Intervention: Prophylactic-treated group (maternal avoidance of cow's milk, egg, and peanut; infant use of casein hydrolysate; avoidance of solid foods for 6 months; cow's milk, corn, soy, citrus, and wheat for 12 months; egg, peanut, and fish for 24 months)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Control group (unrestricted maternal diet; infants followed American Academy of Pediatrics feeding guidelines)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Prophylactic-treated group
Number of subjects: 288

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 288
Study: 14861

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30587323

Group type: EXPERIMENTAL
Intervention: Lenke 1AR curves (n = 43)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Lenke 1AL curves (n = 51)
Number of subjects: 94
Study: 28633671

Group type: EXPERIMENTAL
Intervention: Prucalopride 2 mg/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 40
Study: 26251066

Group type: EXPERIMENTAL
Intervention: Benzylpenicillin
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Amoxicillin combined with sulbactam
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Cefuroxime
Number of subjects: 350

Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 350
Study: 24001747

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (50-μg/d)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Vitamin D2 (50-μg/d)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 21933429

Group type: EXPERIMENTAL
Intervention: Internet-based worksite weight loss program
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Higher income households, higher education levels, and health literacy proficiency
Number of subjects: 19
Study: 18624932

Group type: EXPERIMENTAL
Intervention: Population studies
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Clinic-based studies
Number of subjects: 45
Study: 16683130

Group type: EXPERIMENTAL
Intervention: THA through superior capsulotomy exposure (study group)
Number of subjects: 213

Group type: COMPARATOR
Intervention: THA through direct lateral exposure (control group)
Number of subjects: 213
Study: 12954158

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg daily for 12 months)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 10963459

Group type: EXPERIMENTAL
Intervention: Intravenous ascorbate treatment; specific dosage and duration not mentioned.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral ascorbate treatment; specific dosage and duration not mentioned.
Number of subjects: 0
Study: 2160516

Group type: EXPERIMENTAL
Intervention: 10^4 PFU dose of rhesus rotavirus vaccine
Number of subjects: 320

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: 10^3 PFU dose of rhesus rotavirus vaccine
Number of subjects: 320
Study: 10246464

Group type: EXPERIMENTAL
Intervention: Contingency-contracting approach
Number of subjects: 91

Group type: COMPARATOR
Intervention: Educational approach
Number of subjects: 91

Group type: COMPARATOR
Intervention: Routine-care approach
Number of subjects: 91
Study: 30346660

Group type: EXPERIMENTAL
Intervention: Mercaptopurine 50 mg single oral dose
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Mercaptopurine pharmacokinetics
Number of subjects: 48
Study: 28886083

Group type: EXPERIMENTAL
Intervention: Nurse-led telephone-based intervention
Number of subjects: 768
Study: 26947731

Group type: EXPERIMENTAL
Intervention: Intramedullary fibular allograft (IFA) with locking compression plates (LCPs)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Shoulder hemi-arthroplasty (HA)
Number of subjects: 60
Study: 24552372

Group type: EXPERIMENTAL
Intervention: Leucine supplementation (7 g leucine, 93 kcal, 14.5 g whey-based protein)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Isocaloric isonitrogenous control (0.3 g LEU, 93 kcal, 11.3 g collagen protein)
Number of subjects: 18
Study: 22119991

Group type: EXPERIMENTAL
Intervention: Low fat, high fiber (LFHF) diet
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Modified National Cancer Institute diet supplemented with a soy-based beverage and encapsulated fruit and vegetable juice concentrates (FVJC)
Number of subjects: 51
Study: 20580002

Group type: EXPERIMENTAL
Intervention: Chinese version of the Schizotypal Personality Questionnaire‐Brief
Number of subjects: 618

Group type: COMPARATOR
Intervention: Control group (scores <15)
Number of subjects: 618
Study: 17395894

Group type: EXPERIMENTAL
Intervention: Multilayer-release methylphenidate (qd)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Immediate-release methylphenidate (bid)
Number of subjects: 14
Study: 16311436

Group type: EXPERIMENTAL
Intervention: Oral chondroitin sulfate treatment
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study: 12170105

Group type: EXPERIMENTAL
Intervention: Active tryptophan depletion (concentrated amino acid drink that resulted in a rapid and significant decline in plasma free tryptophan)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo depletion (similar drink containing tryptophan)
Number of subjects: 12
Study: 10502583

Group type: EXPERIMENTAL
Intervention: Topical ofloxacin
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Oral ofloxacin
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Combined administration of ofloxacin
Number of subjects: 31
Study: 7490920

Group type: EXPERIMENTAL
Intervention: Reperfusion therapy (thrombolytic agents or immediate angioplasty)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ancillary treatments to reduce reperfusion injury
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Newer agents (hirudin, glycoprotein IIb-IIIa receptor inhibitors)
Number of subjects: 0
Study: 2614709

Group type: EXPERIMENTAL
Intervention: Pupillary light occluder
Number of subjects: 291

Group type: COMPARATOR
Intervention: No pupillary light occluder
Number of subjects: 291
Study: 6460591

Group type: EXPERIMENTAL
Intervention: Nuva‐Seal
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Delton
Number of subjects: 200
Study: 30948907

Group type: EXPERIMENTAL
Intervention: Robotic hepatectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 27993418

Group type: EXPERIMENTAL
Intervention: Intravenous Ketorolac 10 mg
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Intravenous Ketorolac 15 mg
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Intravenous Ketorolac 30 mg
Number of subjects: 240

Group type: COMPARATOR
Intervention: Rescue analgesic (Intravenous morphine 0.1 mg/kg)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Adverse effects (dizziness, nausea, headache)
Number of subjects: 240
Study: 27012258

Group type: EXPERIMENTAL
Intervention: Familias Unidas intervention
Number of subjects: 367
Study: 24288238

Group type: EXPERIMENTAL
Intervention: Fluoxetine monotherapy (up to 80 mg or maximum tolerated dosage for 12 weeks)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Sequential treatments with add-on strategies: placebo, clomipramine, or quetiapine (for an additional 12 weeks)
Number of subjects: 138
Study: 23192994

Group type: EXPERIMENTAL
Intervention: Cerclage
Number of subjects: 986

Group type: COMPARATOR
Intervention: No cerclage
Number of subjects: 986
Study: 19956961

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg twice daily) and CC
Number of subjects: 43

Group type: COMPARATOR
Intervention: Laparoscopic ovarian drilling (LOD) and CC
Number of subjects: 43
Study: 18329818

Group type: COMPARATOR
Intervention: Placebo (A)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ghrelin (B)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ghrelin and GHRH (C)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ghrelin and CRH (D)
Number of subjects: 10
Study: 15983181

Group type: EXPERIMENTAL
Intervention: High intensity PRT (80% maximum load)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low intensity PRT (20% maximum load)
Number of subjects: 60

Group type: COMPARATOR
Intervention: GP care
Number of subjects: 60
Study: 12027979

Group type: EXPERIMENTAL
Intervention: Loop ileostomy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Loop transverse colostomy
Number of subjects: 80
Study: 10625099

Group type: EXPERIMENTAL
Intervention: 25% metronidazole dental gel applied once a week for two weeks
Number of subjects: 8

Group type: COMPARATOR
Intervention: Scaling and root planing
Number of subjects: 8
Study: 7738616

Group type: EXPERIMENTAL
Intervention: Mesna
Number of subjects: 147

Group type: COMPARATOR
Intervention: Forced diuresis
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Persistent BK viruria
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Single urine sample positive for BK virus
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: No BK virus excretion
Number of subjects: 147
Study: 1697373

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 6407539

Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 12

Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 12
Study: 30022269

Group type: EXPERIMENTAL
Intervention: NeoMTA Plus
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Biodentine
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: MTA Angelus
Number of subjects: 54

Group type: COMPARATOR
Intervention: Negative Control
Number of subjects: 54
Study: 28420726

Group type: EXPERIMENTAL
Intervention: Intraobserver reproducibility assessment with 1% cut point
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intraobserver reproducibility assessment with 50% cut point
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Interobserver reproducibility assessment with 1% cut point
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Interobserver reproducibility assessment with 50% cut point
Number of subjects: 120
Study: 26426736

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25022108

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 54
Study: 22949599

Group type: EXPERIMENTAL
Intervention: Mandibular advancement splint (MAS)
Number of subjects: 90
Study: 20058615

Group type: EXPERIMENTAL
Intervention: Topneuter (Teerjin)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Filgrastim (Huierxue)
Number of subjects: 52
Study: 17584555

Group type: EXPERIMENTAL
Intervention: Trimetazidine (20 mg, 3 times a day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 15363008

Group type: EXPERIMENTAL
Intervention: Nurse-run asthma clinics
Number of subjects: 170

Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 170
Study: 11530028

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg initial dose, titrated to 80 mg if needed)
Number of subjects: 3916

Group type: COMPARATOR
Intervention: Simvastatin (10 mg initial dose, titrated to 40 mg if needed)
Number of subjects: 3916

Group type: COMPARATOR
Intervention: Lovastatin (20 mg initial dose, titrated to 80 mg if needed)
Number of subjects: 3916

Group type: COMPARATOR
Intervention: Pravastatin (10 mg initial dose, titrated to 40 mg if needed)
Number of subjects: 3916

Group type: COMPARATOR
Intervention: Fluvastatin (20 mg initial dose, titrated to 80 mg if needed)
Number of subjects: 3916
Study: 9506347

Group type: EXPERIMENTAL
Intervention: Accelerated hyperfractionated thoracic radiotherapy (AHTRT) with or without chemotherapy
Number of subjects: 99

Group type: COMPARATOR
Intervention: Accelerated hyperfractionated thoracic radiotherapy (AHTRT) with chemotherapy
Number of subjects: 99

Group type: COMPARATOR
Intervention: Standard fractionated thoracic radiotherapy (SFTRT)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Accelerated hyperfractionated thoracic radiotherapy (AHTRT)
Number of subjects: 99
Study: 7997863

Group type: EXPERIMENTAL
Intervention: 0.5 g paracetamol (as propacetamol) intravenously
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 1 g paracetamol (as propacetamol) intravenously
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 2 g paracetamol (as propacetamol) intravenously
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 11
Study: 3287974

Group type: EXPERIMENTAL
Intervention: Cefotetan (2 g single preoperative dose)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Cefoxitin (3 perioperative doses of 2 g)
Number of subjects: 282
Study: 29635699

Group type: EXPERIMENTAL
Intervention: Pulsed-dye laser treatment with a 15 mm diameter beam
Number of subjects: 20
Study: 28794290

Group type: EXPERIMENTAL
Intervention: E-learning self-care education intervention
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control group (no e-learning intervention)
Number of subjects: 131
Study: 25273359

Group type: EXPERIMENTAL
Intervention: Resonating arm exerciser (RAE)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional exercises
Number of subjects: 16
Study: 23233651

Group type: EXPERIMENTAL
Intervention: Perioperative epirubicin, cisplatin and fluorouracil (ECF) chemotherapy
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: HER2 positive pre-treatment biopsies
Number of subjects: 415
Study: 21668343

Group type: EXPERIMENTAL
Intervention: GaAlAs laser
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: NaF varnish
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo laser
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo NaF varnish
Number of subjects: 48
Study: 18310682

Group type: EXPERIMENTAL
Intervention: Operative treatment with plate fixation
Number of subjects: 132

Group type: COMPARATOR
Intervention: Nonoperative treatment with a sling
Number of subjects: 132
Study: 15973669

Group type: EXPERIMENTAL
Intervention: Aprepitant (A) 125 mg orally plus Ondansetron (O) 32 mg and Dexamethasone (D) 12 mg on Day 1; A 80 mg and D 8 mg once daily on Days 2-3; D 8 mg on Day 4
Number of subjects: 1043

Group type: COMPARATOR
Intervention: Control regimen (Ondansetron [O] 32 mg intravenously and Dexamethasone [D] 20 mg orally on Day 1; D 8 mg twice daily on Days 2-4)
Number of subjects: 1043

Group type: EXPERIMENTAL
Intervention: Aprepitant (A) regimen
Number of subjects: 1043
Study: 12921622

Group type: EXPERIMENTAL
Intervention: rhEGF
Number of subjects: 37

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 37
Study: 10572606

Group type: EXPERIMENTAL
Intervention: MACOP-B (6-drug weekly chemotherapy regimen for 12 weeks)
Number of subjects: 374

Group type: COMPARATOR
Intervention: CHOP (standard regimen for 24 weeks)
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: MACOP-B
Number of subjects: 374

Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 374
Study: 8667538

Group type: EXPERIMENTAL
Intervention: Famciclovir (125mg, 250mg, 500mg)
Number of subjects: 692

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 692
Study: 1852297

Group type: EXPERIMENTAL
Intervention: Methoxybutropate (300 mg three times a day for eight weeks)
Number of subjects: 20
Study: 6558291

Group type: EXPERIMENTAL
Intervention: Activity-centered health education curriculum
Number of subjects: 234

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 234
Study: 30403976

Group type: EXPERIMENTAL
Intervention: Early Oral Feeding (EOF) group
Number of subjects: 86

Group type: COMPARATOR
Intervention: Late Oral Feeding (LOF) group
Number of subjects: 86
Study: 30170808

Group type: EXPERIMENTAL
Intervention: QTer® and Creatine supplementation
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 27822013

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination (FDC) of clopidogrel/aspirin 75/100 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Coadministration of individual formulations (clopidogrel 75 mg and aspirin 100 mg)
Number of subjects: 60
Study: 24381272

Group type: EXPERIMENTAL
Intervention: Highly focused spatial attention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Distributed attention
Number of subjects: 0
Study: 21420744

Group type: EXPERIMENTAL
Intervention: Withdrawal of psychotropic drugs
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Withdrawal of benzodiazepine or related drugs (BZD/BZDRD)
Number of subjects: 528

Group type: COMPARATOR
Intervention: Control group (not ceasing drug use)
Number of subjects: 528
Study: 21041350

Group type: EXPERIMENTAL
Intervention: Collaborative care intervention including patient education and choice of medication, therapy, or both.
Number of subjects: 339

Group type: COMPARATOR
Intervention: Enhanced usual care (control group).
Number of subjects: 339
Study: 17597349

Group type: EXPERIMENTAL
Intervention: Lymphadenectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Resection without lymphadenectomy
Number of subjects: 0
Study: 12890430

Group type: EXPERIMENTAL
Intervention: IGIV-C (Gamunex, 10%)
Number of subjects: 172

Group type: COMPARATOR
Intervention: IGIV-SD (Gamimune N, 10%)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Both IGIV-C and IGIV-SD
Number of subjects: 172
Study: 10743445

Group type: EXPERIMENTAL
Intervention: meloxicam 15 mg rectally
Number of subjects: 36

Group type: COMPARATOR
Intervention: placebo suppository
Number of subjects: 36
Study: 8729661

Group type: EXPERIMENTAL
Intervention: Two-stage double-blind, placebo-controlled food challenge (DBPCFC) for immediate reactors
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Two-stage double-blind, placebo-controlled food challenge (DBPCFC) for delayed reactors
Number of subjects: 69

Group type: COMPARATOR
Intervention: Skin-prick tests (SPTs)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Enzyme allergosorbent test (EAST)
Number of subjects: 69
Study: 1553891

Group type: EXPERIMENTAL
Intervention: Bepridil 200 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bepridil 300 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bepridil 400 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bepridil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2581680

Group type: EXPERIMENTAL
Intervention: 0.5 mg intrathecal morphine (Group B)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 1 mg intrathecal morphine (Group C)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Prilocaine 100 mg (Group A, Control)
Number of subjects: 45
Study: 30155645

Group type: EXPERIMENTAL
Intervention: Burr hole cover placement
Number of subjects: 28

Group type: COMPARATOR
Intervention: No burr hole cover placement (Control)
Number of subjects: 28
Study: 26670617

Group type: EXPERIMENTAL
Intervention: Hydroxycarbamide (20 mg/kg per day, escalated to maximum tolerated dose)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Standard transfusions (monthly to maintain 30% sickle haemoglobin or lower)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Hydroxycarbamide
Number of subjects: 121

Group type: COMPARATOR
Intervention: Standard transfusions
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 121
Study: 24690513

Group type: EXPERIMENTAL
Intervention: Nicotine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16